New drug duo targets Tough-to-Treat ovarian cancer
NCT ID NCT05296512
Summary
This study is testing whether combining two existing cancer drugs—pembrolizumab and lenvatinib—can help control recurrent clear cell ovarian cancer. The trial will enroll about 30 patients whose cancer has returned after prior treatment. Researchers will measure how well the combination shrinks tumors, how long it keeps cancer from progressing, and what side effects patients experience.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota, 55905, United States
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.